Shanu Modi

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer
    Shanu Modi
    Memorial Sloan Kettering Cancer Center Weill Cornell Medical College, 300 East 66th Street, New York, NY 10065, USA
    Breast Cancer Res Treat 139:107-13. 2013
  2. doi request reprint HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Cancer Res 17:5132-9. 2011
  3. ncbi request reprint Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5410-7. 2007
  4. ncbi request reprint A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer
    Shanu Modi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 7:270-7. 2006
  5. ncbi request reprint Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Invest 23:483-7. 2005
  6. ncbi request reprint Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane
    Monica N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:1575-9. 2005
  7. ncbi request reprint A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Breast Cancer Res Treat 90:157-63. 2005
  8. doi request reprint A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors
    Komal Jhaveri
    Memorial Sloan Kettering Cancer Center Weill Cornell Medical College, New York, NY 10032, USA
    Clin Cancer Res 18:5090-8. 2012
  9. pmc Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer
    Volkan Beylergil
    aDepartment of Radiology, Molecular Imaging and Therapy Service bDepartment of Medicine, Breast Cancer Medicine Service cHuman Oncology and Pathogenesis Program dDepartment of Medical Physics eRadiochemistry and Molecular Imaging Probes Core Facility, Memorial Sloan Kettering Cancer Center Departments of fRadiology gMedicine, Weill Cornell Medical College, New York, New York, USA
    Nucl Med Commun 34:1157-65. 2013
  10. ncbi request reprint A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 6:55-60. 2005

Collaborators

Detail Information

Publications21

  1. pmc A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer
    Shanu Modi
    Memorial Sloan Kettering Cancer Center Weill Cornell Medical College, 300 East 66th Street, New York, NY 10065, USA
    Breast Cancer Res Treat 139:107-13. 2013
    ..The safety profile for patients on study raises the possibility of retaspimycin HCl underdosing that limited efficacy. Studies employing higher doses are ongoing...
  2. doi request reprint HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Cancer Res 17:5132-9. 2011
    ..On the basis of these data and activity in a phase I study, we conducted a phase II study of 17-AAG (tanespimycin) with trastuzumab in advanced trastuzumab-refractory HER2-positive breast cancer...
  3. ncbi request reprint Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5410-7. 2007
    ..This phase I study examined whether a heat shock protein (Hsp) 90 inhibitor tanespimycin (17-AAG; KOS-953) could be administered safely in combination with trastuzumab at a dose that inhibits Hsp90 function in vivo in lymphocytes...
  4. ncbi request reprint A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer
    Shanu Modi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 7:270-7. 2006
    ..Preclinical studies have indicated a synergistic effect for the combination of anti-EGFR therapy plus paclitaxel in breast cancer models...
  5. ncbi request reprint Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Invest 23:483-7. 2005
    ..046). Functional assessment of HER2 status may provide unique predictive information not seen with conventional assessments...
  6. ncbi request reprint Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane
    Monica N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:1575-9. 2005
    ....
  7. ncbi request reprint A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Breast Cancer Res Treat 90:157-63. 2005
    ..Breast cancer has variable expression of KIT and PDGFR therefore we conducted a phase II trial to evaluate the safety and efficacy of imatinib in patients with metastatic breast cancer (MBC)...
  8. doi request reprint A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors
    Komal Jhaveri
    Memorial Sloan Kettering Cancer Center Weill Cornell Medical College, New York, NY 10032, USA
    Clin Cancer Res 18:5090-8. 2012
    ....
  9. pmc Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer
    Volkan Beylergil
    aDepartment of Radiology, Molecular Imaging and Therapy Service bDepartment of Medicine, Breast Cancer Medicine Service cHuman Oncology and Pathogenesis Program dDepartment of Medical Physics eRadiochemistry and Molecular Imaging Probes Core Facility, Memorial Sloan Kettering Cancer Center Departments of fRadiology gMedicine, Weill Cornell Medical College, New York, New York, USA
    Nucl Med Commun 34:1157-65. 2013
    ....
  10. ncbi request reprint A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 6:55-60. 2005
    ..Gemcitabine was delivered at a dose of 800 mg/m2 on days 1, 8, and 15 of a 28-day cycle until evidence of disease progression...
  11. pmc Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer
    Sarat Chandarlapaty
    Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 18:6784-91. 2012
    ..We conducted a prospective tissue acquisition study to determine if there is evidence for these lesions in metastatic tumors that have progressed on trastuzumab-containing therapy...
  12. doi request reprint A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:3398-407. 2011
    ..We evaluated the cardiac safety of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (ddAC) → nanoparticle albumin-bound (nab)-paclitaxel in human epidermal growth factor receptor 2 normal early-stage breast cancer...
  13. pmc Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer
    Patrick G Morris
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 E 66th St, New York, NY 10065, USA
    Cancer Prev Res (Phila) 6:428-36. 2013
    ....
  14. doi request reprint Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Breast Cancer 10:33-9. 2010
    ..A prospective clinical study was designed to explore this hypothesis. Patients and..
  15. ncbi request reprint An update on epidermal growth factor receptor inhibitors
    Shanu Modi
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 4:47-55. 2002
    ..Promising new compounds in the advanced stages of clinical testing are emphasized...
  16. ncbi request reprint HSP90 inhibitors for cancer therapy and overcoming drug resistance
    Komal Jhaveri
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY, USA
    Adv Pharmacol 65:471-517. 2012
    ....
  17. ncbi request reprint Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer
    Shanu Modi
    Breast Cancer Medicine Service, Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:3665-73. 2002
    ..To prospectively evaluate the association between tumor response, change in quality of life (QoL), and hospital expenditures in patients with metastatic breast cancer (MBC) receiving single-agent paclitaxel...
  18. ncbi request reprint Preoperative chemotherapy for breast cancer: miracle or mirage?
    Clifford Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill College of Medicine, Cornell University, New York, New York 10024, USA
    JAMA 298:2665-7. 2007
  19. ncbi request reprint Single-agent gemcitabine in the treatment of advanced breast cancer
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 4:S101-6. 2004
    ....
  20. ncbi request reprint A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer
    Komal Jhaveri
    Memorial Sloan Kettering Cancer Center, New York, NY
    Clin Breast Cancer 14:154-60. 2014
    ..We therefore tested ganetespib in an unselected cohort of patients with MBC...
  21. pmc Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
    Komal Jhaveri
    Department of Medicine, Breast Cancer Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Biochim Biophys Acta 1823:742-55. 2012
    ..Ultimately, these efforts will aid in maximizing the full potential of this class of agents. This article is part of a Special Issue entitled: Heat Shock Protein 90 (HSP90)...